Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Ca.O4S |
| Molecular Weight | 136.141 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].[O-]S([O-])(=O)=O
InChI
InChIKey=OSGAYBCDTDRGGQ-UHFFFAOYSA-L
InChI=1S/Ca.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
| Molecular Formula | O4S |
| Molecular Weight | 96.063 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
| C-reactive protein in the hemolymph of Achatina fulica: interrelationship with sex steroids and metallothionein. | 2000 Apr |
|
| Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density. | 2000 Aug |
|
| Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. | 2000 Dec |
|
| NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. | 2000 Jul 17 |
|
| Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A. | 2000 May |
|
| Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway. | 2000 May |
|
| Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
| Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. | 2000 Nov 10 |
|
| Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
| Chemokines induce eosinophil degranulation through CCR-3. | 2000 Sep |
|
| ATP induces dephosphorylation of myosin light chain in endothelial cells. | 2000 Sep |
|
| Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake. | 2000 Sep |
|
| Characterization of the human cysteinyl leukotriene 2 receptor. | 2000 Sep 29 |
|
| Ca2+-induced contraction of cat esophageal circular smooth muscle cells. | 2001 Apr |
|
| Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
| Analysis of the native quaternary structure of vanilloid receptor 1. | 2001 Jul 27 |
|
| Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B. | 2001 Jun |
|
| Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy. | 2001 Jun 8 |
|
| Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
| Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. | 2001 Mar |
|
| Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
| Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
| Familial intrahepatic cholestasis 1: studies of localization and function. | 2001 Oct |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
| Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels. | 2001 Oct 12 |
|
| Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore. | 2001 Sep 1 |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
| Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
| Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. | 2009 Jul-Aug |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:56 GMT 2025
by
admin
on
Mon Mar 31 18:09:56 GMT 2025
|
| Record UNII |
E934B3V59H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-516
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
||
|
JECFA EVALUATION |
INS-516
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
||
|
CFR |
21 CFR 178.3297
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C45678
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
529649
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
902
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
DTXSID9029699
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
100000090253
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
C65282
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
31346
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
1328529
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | RxNorm | ||
|
E934B3V59H
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
E934B3V59H
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
231-900-3
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
7778-18-9
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
m2978
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
24497
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY | |||
|
SUB36939
Created by
admin on Mon Mar 31 18:09:56 GMT 2025 , Edited by admin on Mon Mar 31 18:09:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
